Related Experiment Videos
[Antigenicity test of cefodizime sodium]
M Takemoto1, K Matsuo, S Katoh
1Daiichi Pure Chemicals Co. Ltd., Tokai Research Laboratories, Tokai-mura Ibaraki-ken, Japan.
The Journal of Toxicological Sciences
|June 1, 1988
Summary
Cefodizime sodium (THR-221) exhibits immunological activity comparable to other beta-lactam antibiotics. Studies in mice and guinea pigs showed it induced antibodies and cross-reactivity, with generally lower antigenicity than some comparators.
Area of Science:
- Immunology
- Pharmacology
- Microbiology
Background:
- Beta-lactam antibiotics are widely used, but their immunogenicity requires careful evaluation.
- Understanding the antigenicity of new beta-lactam antibiotics like cefodizime sodium (THR-221) is crucial for clinical safety.
- Previous studies on antibiotic immunogenicity provide a basis for comparing new agents.
Purpose of the Study:
- To investigate the antigenicity of cefodizime sodium (THR-221) in animal models.
- To compare the immunological activity of THR-221 with other beta-lactam antibiotics.
- To assess the potential for allergic reactions associated with THR-221.
Main Methods:
- Passive cutaneous anaphylaxis (PCA) in mice and guinea pigs.
- Active systemic anaphylaxis (ASA) in guinea pigs.
- Passive hemagglutination (PHA) assays.
- Protein binding assays with human serum albumin.
Main Results:
- THR-221 induced antibodies and showed cross-reactivity with cefmetazole (CMZ) in PCA reactions.
- Active systemic anaphylaxis was observed in guinea pigs sensitized with THR-221 and Freund's complete adjuvant (FCA).
- Passive hemagglutination titers and protein binding of THR-221 were generally lower than those of CMZ.
Conclusions:
- Immunological activity of cefodizime sodium (THR-221) is comparable to other beta-lactam antibiotics.
- THR-221 demonstrates some antigenicity, necessitating consideration of potential hypersensitivity reactions.
- Further clinical studies may be warranted to fully elucidate the immunogenic profile of THR-221.